Market revenue in 2023 | USD 8,145.4 million |
Market revenue in 2030 | USD 11,286.4 million |
Growth rate | 4.8% (CAGR from 2023 to 2030) |
Largest segment | Cell wall synthesis inhibitors |
Fastest growing segment | RNA Synthesis Inhibitors |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors |
Key market players worldwide | AbbVie Inc, Pfizer Inc, Novartis AG ADR, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Lupin, Viatris Inc, Melinta Therapeutics, Cipla Ltd DR, Shionogi & Co Ltd, GSK PLC, Kyorin Pharmaceutical, Nabriva Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibiotics market will help companies and investors design strategic landscapes.
Cell wall synthesis inhibitors was the largest segment with a revenue share of 54.2% in 2023. Horizon Databook has segmented the China antibiotics market based on cell wall synthesis inhibitors, protein synthesis inhibitors, dna synthesis inhibitors, rna synthesis inhibitors, mycolic acid inhibitors covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the China antibiotics market , including forecasts for subscribers. This country databook contains high-level insights into China antibiotics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account